Asthma control using fluticasone propionate/salmeterol in Asian and non-Asian populations: a post hoc analysis of the GOAL study
Abstract Background To analyse the efficacy of fluticasone propionate (FP) alone and combined with salmeterol (SAL) in achieving guideline-defined asthma control in Asian patients. Methods A post hoc analysis of the GOAL study in which patients were stratified by prior-medication use into inhaled co...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2017-04-01
|
Series: | BMC Pulmonary Medicine |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12890-017-0410-x |
_version_ | 1819092571360591872 |
---|---|
author | Jean Bousquet Neil Barnes Michael Gibbs Nadeem Gul Susan A Tomkins Xin Zhou Young-Joo Cho Hae-Sim Park William Busse Nanshan Zhong |
author_facet | Jean Bousquet Neil Barnes Michael Gibbs Nadeem Gul Susan A Tomkins Xin Zhou Young-Joo Cho Hae-Sim Park William Busse Nanshan Zhong |
author_sort | Jean Bousquet |
collection | DOAJ |
description | Abstract Background To analyse the efficacy of fluticasone propionate (FP) alone and combined with salmeterol (SAL) in achieving guideline-defined asthma control in Asian patients. Methods A post hoc analysis of the GOAL study in which patients were stratified by prior-medication use into inhaled corticosteroid (ICS)-naïve (Stratum [S] 1), low-dose ICS (S2), and medium-dose ICS (S3), and randomised to receive FP/SAL or FP. Doses were stepped-up every 12 weeks until Totally Controlled asthma or maximum dose was reached (PhI) and then maintained until study end (PhII). The primary endpoint was the proportion of patients achieving Well-Controlled asthma during PhI. Additional endpoints included Total Control and adverse events. Asian and non-Asian patients were analysed separately. Results In Asian patients in PhI, 74% (n = 87/118) in S1 achieved Well-Controlled asthma with FP/SAL versus 74% (n = 89/121) with FP alone (p = 0.839); corresponding values were 76% (n = 81/107) versus 60% (n = 62/104; p = 0.005) in S2, and 58% (n = 59/102) versus 43% (n = 41/95; p = 0.015) in S3. More patients in all three strata achieved Totally Controlled asthma with FP/SAL versus FP alone. Control was achieved more rapidly and with lower ICS doses with FP/SAL versus FP. A high proportion of patients who achieved control during PhI maintained control during PhII. Similar trends were found in non-Asian patients. No new safety concerns were identified. Conclusions A greater proportion of Asian patients (S2 and S3, for Well-Controlled; all strata, for Totally Controlled) achieved guideline-defined asthma control with FP/SAL versus FP alone. High proportions of Asian patients in S1 achieved Well-Controlled asthma in both treatment groups. |
first_indexed | 2024-12-21T22:57:44Z |
format | Article |
id | doaj.art-1b57930019464b279e8c59e559ad5f2e |
institution | Directory Open Access Journal |
issn | 1471-2466 |
language | English |
last_indexed | 2024-12-21T22:57:44Z |
publishDate | 2017-04-01 |
publisher | BMC |
record_format | Article |
series | BMC Pulmonary Medicine |
spelling | doaj.art-1b57930019464b279e8c59e559ad5f2e2022-12-21T18:47:23ZengBMCBMC Pulmonary Medicine1471-24662017-04-0117111210.1186/s12890-017-0410-xAsthma control using fluticasone propionate/salmeterol in Asian and non-Asian populations: a post hoc analysis of the GOAL studyJean Bousquet0Neil Barnes1Michael Gibbs2Nadeem Gul3Susan A Tomkins4Xin Zhou5Young-Joo Cho6Hae-Sim Park7William Busse8Nanshan Zhong9Fondation MACVIA-LR, Contre les Maladies Chroniques pour un Vieillissement Actif en Languedoc-Roussillon, European Innovation Partnership on Active and Healthy Ageing Reference Site, University of MontpellierGlobal Respiratory Franchise, GSK HouseGlobal Respiratory Franchise, GSK HouseQuantitative Science, Clinical Statistics, GSKQuantitative Science, Clinical Statistics, GSKShanghai First People’s HospitalEwha Womans University, School of MedicineAjou University Medical CenterUniversity of Wisconsin, School of Medicine and Public HealthState Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical UniversityAbstract Background To analyse the efficacy of fluticasone propionate (FP) alone and combined with salmeterol (SAL) in achieving guideline-defined asthma control in Asian patients. Methods A post hoc analysis of the GOAL study in which patients were stratified by prior-medication use into inhaled corticosteroid (ICS)-naïve (Stratum [S] 1), low-dose ICS (S2), and medium-dose ICS (S3), and randomised to receive FP/SAL or FP. Doses were stepped-up every 12 weeks until Totally Controlled asthma or maximum dose was reached (PhI) and then maintained until study end (PhII). The primary endpoint was the proportion of patients achieving Well-Controlled asthma during PhI. Additional endpoints included Total Control and adverse events. Asian and non-Asian patients were analysed separately. Results In Asian patients in PhI, 74% (n = 87/118) in S1 achieved Well-Controlled asthma with FP/SAL versus 74% (n = 89/121) with FP alone (p = 0.839); corresponding values were 76% (n = 81/107) versus 60% (n = 62/104; p = 0.005) in S2, and 58% (n = 59/102) versus 43% (n = 41/95; p = 0.015) in S3. More patients in all three strata achieved Totally Controlled asthma with FP/SAL versus FP alone. Control was achieved more rapidly and with lower ICS doses with FP/SAL versus FP. A high proportion of patients who achieved control during PhI maintained control during PhII. Similar trends were found in non-Asian patients. No new safety concerns were identified. Conclusions A greater proportion of Asian patients (S2 and S3, for Well-Controlled; all strata, for Totally Controlled) achieved guideline-defined asthma control with FP/SAL versus FP alone. High proportions of Asian patients in S1 achieved Well-Controlled asthma in both treatment groups.http://link.springer.com/article/10.1186/s12890-017-0410-xAsian patientsAsthmaAsthma controlAsthma treatmentFluticasone propionate/salmeterolICS/LABA treatment |
spellingShingle | Jean Bousquet Neil Barnes Michael Gibbs Nadeem Gul Susan A Tomkins Xin Zhou Young-Joo Cho Hae-Sim Park William Busse Nanshan Zhong Asthma control using fluticasone propionate/salmeterol in Asian and non-Asian populations: a post hoc analysis of the GOAL study BMC Pulmonary Medicine Asian patients Asthma Asthma control Asthma treatment Fluticasone propionate/salmeterol ICS/LABA treatment |
title | Asthma control using fluticasone propionate/salmeterol in Asian and non-Asian populations: a post hoc analysis of the GOAL study |
title_full | Asthma control using fluticasone propionate/salmeterol in Asian and non-Asian populations: a post hoc analysis of the GOAL study |
title_fullStr | Asthma control using fluticasone propionate/salmeterol in Asian and non-Asian populations: a post hoc analysis of the GOAL study |
title_full_unstemmed | Asthma control using fluticasone propionate/salmeterol in Asian and non-Asian populations: a post hoc analysis of the GOAL study |
title_short | Asthma control using fluticasone propionate/salmeterol in Asian and non-Asian populations: a post hoc analysis of the GOAL study |
title_sort | asthma control using fluticasone propionate salmeterol in asian and non asian populations a post hoc analysis of the goal study |
topic | Asian patients Asthma Asthma control Asthma treatment Fluticasone propionate/salmeterol ICS/LABA treatment |
url | http://link.springer.com/article/10.1186/s12890-017-0410-x |
work_keys_str_mv | AT jeanbousquet asthmacontrolusingfluticasonepropionatesalmeterolinasianandnonasianpopulationsaposthocanalysisofthegoalstudy AT neilbarnes asthmacontrolusingfluticasonepropionatesalmeterolinasianandnonasianpopulationsaposthocanalysisofthegoalstudy AT michaelgibbs asthmacontrolusingfluticasonepropionatesalmeterolinasianandnonasianpopulationsaposthocanalysisofthegoalstudy AT nadeemgul asthmacontrolusingfluticasonepropionatesalmeterolinasianandnonasianpopulationsaposthocanalysisofthegoalstudy AT susanatomkins asthmacontrolusingfluticasonepropionatesalmeterolinasianandnonasianpopulationsaposthocanalysisofthegoalstudy AT xinzhou asthmacontrolusingfluticasonepropionatesalmeterolinasianandnonasianpopulationsaposthocanalysisofthegoalstudy AT youngjoocho asthmacontrolusingfluticasonepropionatesalmeterolinasianandnonasianpopulationsaposthocanalysisofthegoalstudy AT haesimpark asthmacontrolusingfluticasonepropionatesalmeterolinasianandnonasianpopulationsaposthocanalysisofthegoalstudy AT williambusse asthmacontrolusingfluticasonepropionatesalmeterolinasianandnonasianpopulationsaposthocanalysisofthegoalstudy AT nanshanzhong asthmacontrolusingfluticasonepropionatesalmeterolinasianandnonasianpopulationsaposthocanalysisofthegoalstudy |